TY - JOUR T1 - Effect of Renin-Angiotensin-Aldosterone System inhibitors on outcomes of COVID-19 patients with hypertension: Systematic review and Meta-analysis JF - medRxiv DO - 10.1101/2020.09.03.20187393 SP - 2020.09.03.20187393 AU - Tamirat Bekele Beressa AU - Tamiru Sahilu AU - Serawit Deyno Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/09/04/2020.09.03.20187393.abstract N2 - Objective This research aimed to systematically review and summarize the influence of Renin-Angiotensin-Aldosterone System (RAAS) inhibitors on the outcome of COVID_19 patients with hypertension.Methods Electronic databases; PubMed/Medline, CINAHL, the Cochrane Central Register of Controlled Trials, clinical trial.gov, and Google Scholar were searched from 2019 to June 1, 2020. Additionally, the references of identified articles were also searched.Results A total of 9 articles comprising 3,823 patients were incorporated; 1416 patients on RAAS inhibitors and 3469 on non-RAAS inhibitors. The study demonstrated that the taking of RAAS inhibitors in COVID_19 patients with hypertension significantly reduced mortality where patients on RAAS inhibitors had a 27% decrease of mortality (RR = 0.73 [95% CI: 0.63- 0.85, p< 0.0001, I2 = 0%, random-effects model]) compared to those not taking ACEI/ARB. No significant association were observed in disease severity (RR = 0.92 (95% CI: 0.74- 1.14) and hospitalization (WMD = –2.33[95% CI: –5.60, 0.75]), random-effects model.Conclusion This study supports RAAS inhibitors’ safe use among COVID_19 patients with hypertension.Competing Interest StatementThe authors have declared no competing interest.Funding StatementN/AAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The protocol was registered in the International Prospective Register of Systematic review with registration number CDR42020186477.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesN/ACOVID_19Corona viral diseases 2019SARS-CoV-2severe acute respiratory syndrome coronavirus 2CDCCenter of Disease ControlRAASrenin-angiotensin-aldosterone systemACEIAngiotensin-converting enzyme inhibitorsARBAngiotensin receptor blockerACE2angiotensin-converting enzyme 2Ang IIAngiotensin IIPRISMA-PSystematic Review and Meta-Analysis ProtocolRCTsrandomized controlled trialsCCBCalcium channel blocker. ER -